PA
TRVI icon

Profund Advisors’s Trevi Therapeutics TRVI Stock Holding History

Profund Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$394K Sell
21,106
-8
-0% -$116 0.01% 655
2026
Q1 		$252K Buy
21,114
+1,736
+9% +$19.4K 0.01% 872
2025
Q4 		$243K Sell
19,378
-725
-4% -$8.38K 0.01% 1030
2025
Q3 		$184K Buy
20,103
+2,044
+11% +$15.3K 0.01% 997
2025
Q2 		$98.8K Buy
+18,059
New +$112K ﹤0.01% 967

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Profund Advisors's TRVI Position: Q2 2026 in Review

Profund Advisors reduced its Trevi Therapeutics (TRVI) stake by 0.04% in Q2 2026, selling an estimated $116 and leaving 21,106 shares worth $394K. The position accounts for 0.01% of the portfolio, ranked #655.

Profund Advisors first reported a position in TRVI in Q2 2025 and has held it in 5 quarters since. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Profund Advisors held 21,106 shares of Trevi Therapeutics worth $394K as of Q2 2026.
  • Profund Advisors sold 8 Trevi Therapeutics shares in Q2 2026, an estimated $116.
  • Trevi Therapeutics made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #655 holding.
  • Profund Advisors first reported a position in Trevi Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.